Trial Profile
A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Infants With Type 1 Spinal Muscular Atrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms FIREFISH
- Sponsors Chugai Pharmaceutical; Roche
- 01 Feb 2024 This trial has been Completed in Poland, According to European Clinical Trials Database record.
- 22 Dec 2023 Status changed from active, no longer recruiting to completed.
- 14 Nov 2023 The protocol has been amended to change in phase II/III to Phase II with no change in other study parameters.